Speaker:

Kirollos S. Hanna, PharmD, BCPS, BCOP

Oncology Pharmacy Manager
M Health Fairview
Maple Grove, Minnesota

Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota

Kirollos S. Hanna, PharmD, BCPS, BCOP, has the following relevant financial relationships with commercial interests to disclose:

• Consultant: AbbVie, Seagen
• Speakers Bureau: AbbVie, Astellas, BeiGene, Bristol Myers Squibb, Exelixis, Seagen

At the completion of this activity, pharmacists, physicians, and nurses will be able to:

• Characterize potential biomarkers to optimize the selection of patients with bladder cancer eligible for immune checkpoint inhibitors and targeted agents.
• Explain the benefits and limitations of current guideline-based treatments for bladder cancer and the appropriate use of novel and emerging agents.
• Apply recent and emerging data to tailor treatment regimens for patients with bladder cancer.

At the completion of this activity, pharmacy technicians will be able to:

• Articulate the rationale for use of biomarkers in selection of therapy for patients with bladder cancer
• Discuss the benefits and limitations of current guideline-based treatments for bladder cancer.
• Recall place in therapy of new and emerging agents for patients with bladder cancer.

Activity Overview

In patients with bladder cancer, the use of biomarkers to predict response to therapy and assess prognosis is growing. In patients who are unable to tolerate platinum agents or whose tumors express PD-L1, immune checkpoint inhibitors have a significant role. To prevent disease recurrence and progression, timely recognition and appropriate management is imperative, and practitioners on the oncology care team must stay ahead of advancements in biomarker testing, maintenance therapy options, and expanded indications to determine targeted approaches to treatment. Evidence supporting use of immunotherapeutic and targeted therapies in patients will be presented to assist members of the oncology care team in making proactive treatment decisions and individualized management plans for patients with bladder cancer in accordance with guideline recommendations.